Advanced glycation end-products (AGEs)

A novel therapeutic target for osteoporosis in patients with rheumatoid arthritis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bone losses in patients with rheumatoid arthritis (RA) include focal marginal joint erosion, juxtaarticular osteopenia, and systemic osteoporosis. Systemic osteoporosis prevalent in RA is associated with increased fracture rates and is a cause of very high morbidity and mortality. A couple of reports showed that advanced glycation end-products (AGEs) influence osteoclasts (bone resorption) and osteoblasts (bone formation), so AGEs may be have an important role in the pathogenesis of osteoporotic bone diseases. Recently, it was demonstrated that AGEs is increased in patients with RA and the concentration of AGEs correlates with the disease activity of RA. We present a hypothesis that AGEs may be involved in the pathogenesis of osteoporosis in patients with RA and the AGE crosslink breaker alagebrium will be a powerful therapeutic agent for osteoporosis in patients with RA.

Original languageEnglish
Pages (from-to)201-202
Number of pages2
JournalMedical Hypotheses
Volume73
Issue number2
DOIs
Publication statusPublished - 2009 Aug 1

Fingerprint

Advanced Glycosylation End Products
Osteoporosis
Rheumatoid Arthritis
Therapeutics
Metabolic Bone Diseases
Bone Diseases
Osteoclasts
Bone Resorption
Osteoblasts
Osteogenesis
Joints
Morbidity
Bone and Bones
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{e29074a46a624ef8895d18903cde6236,
title = "Advanced glycation end-products (AGEs): A novel therapeutic target for osteoporosis in patients with rheumatoid arthritis",
abstract = "Bone losses in patients with rheumatoid arthritis (RA) include focal marginal joint erosion, juxtaarticular osteopenia, and systemic osteoporosis. Systemic osteoporosis prevalent in RA is associated with increased fracture rates and is a cause of very high morbidity and mortality. A couple of reports showed that advanced glycation end-products (AGEs) influence osteoclasts (bone resorption) and osteoblasts (bone formation), so AGEs may be have an important role in the pathogenesis of osteoporotic bone diseases. Recently, it was demonstrated that AGEs is increased in patients with RA and the concentration of AGEs correlates with the disease activity of RA. We present a hypothesis that AGEs may be involved in the pathogenesis of osteoporosis in patients with RA and the AGE crosslink breaker alagebrium will be a powerful therapeutic agent for osteoporosis in patients with RA.",
author = "Ji, {Jong Dae} and Woo, {Jin Hyun} and Sungjae Choi and Lee, {Young Ho} and Song, {Gwan Gyu}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.mehy.2009.02.020",
language = "English",
volume = "73",
pages = "201--202",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Advanced glycation end-products (AGEs)

T2 - A novel therapeutic target for osteoporosis in patients with rheumatoid arthritis

AU - Ji, Jong Dae

AU - Woo, Jin Hyun

AU - Choi, Sungjae

AU - Lee, Young Ho

AU - Song, Gwan Gyu

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Bone losses in patients with rheumatoid arthritis (RA) include focal marginal joint erosion, juxtaarticular osteopenia, and systemic osteoporosis. Systemic osteoporosis prevalent in RA is associated with increased fracture rates and is a cause of very high morbidity and mortality. A couple of reports showed that advanced glycation end-products (AGEs) influence osteoclasts (bone resorption) and osteoblasts (bone formation), so AGEs may be have an important role in the pathogenesis of osteoporotic bone diseases. Recently, it was demonstrated that AGEs is increased in patients with RA and the concentration of AGEs correlates with the disease activity of RA. We present a hypothesis that AGEs may be involved in the pathogenesis of osteoporosis in patients with RA and the AGE crosslink breaker alagebrium will be a powerful therapeutic agent for osteoporosis in patients with RA.

AB - Bone losses in patients with rheumatoid arthritis (RA) include focal marginal joint erosion, juxtaarticular osteopenia, and systemic osteoporosis. Systemic osteoporosis prevalent in RA is associated with increased fracture rates and is a cause of very high morbidity and mortality. A couple of reports showed that advanced glycation end-products (AGEs) influence osteoclasts (bone resorption) and osteoblasts (bone formation), so AGEs may be have an important role in the pathogenesis of osteoporotic bone diseases. Recently, it was demonstrated that AGEs is increased in patients with RA and the concentration of AGEs correlates with the disease activity of RA. We present a hypothesis that AGEs may be involved in the pathogenesis of osteoporosis in patients with RA and the AGE crosslink breaker alagebrium will be a powerful therapeutic agent for osteoporosis in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=67349264558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349264558&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2009.02.020

DO - 10.1016/j.mehy.2009.02.020

M3 - Article

VL - 73

SP - 201

EP - 202

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 2

ER -